...
首页> 外文期刊>Regulatory peptides. >Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension.
【24h】

Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension.

机译:未经治疗的轻度至中度高血压患者的循环生长素释放肽和生长素释放肽与肥胖抑制素的比率较低。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Obestatin, encoded by the same gene as ghrelin, was first described as a physiological opponent of ghrelin. We investigated fasting plasma ghrelin and obestatin levels and ratio of ghrelin to obestatin in humans with untreated mild-to-moderate hypertension and humans with normal blood pressure. We found that the plasma concentration of ghrelin and the ratio of ghrelin to obestatin were significantly lower in hypertension group compared with control group (236.3+/-12.3 pg/ml vs 381.4+/-25.6 pg/ml, P<0.01; 0.89+/-0.06 vs 1.2+/-0.06, P<0.01). The plasma concentration of obestatin was lower in hypertension group compared with control group, but the difference between the two groups was not significant (276.2+/-15.1 pg/ml vs 325.4+/-25.8 pg/ml, P>0.05). In a multiple regression model, systolic blood pressure, triglyceride and obestatin were independent predictors of ghrelin (standardized coefficient=-0.332; P=0.019; standardized coefficient=-0.302; P=0.030; standardized coefficient=0.630; P<0.0005, respectively). In another multiple regression model, only ghrelin was an independent predictor of obestatin (standardized coefficient=0.861; P<0.0005). Both systolic blood pressure and triglyceride were independent predictors of ratio of ghrelin to obestatin (standardized coefficient=-0.385; P=0.033; standardized coefficient=-0.430; P=0.018, respectively). Our data suggests that there are disturbances of ghrelin and obestatin in the circulating plasma of humans and the ghrelin/obestatin system might play a role in blood pressure regulation.
机译:肥胖抑制素由与生长素释放肽相同的基因编码,最初被描述为生长素释放肽的生理对手。我们研究了未经治疗的轻至中度高血压的人和血压正常的人的空腹血浆生长素释放肽和肥胖抑制素水平以及生长素释放肽与肥胖抑制素的比率。我们发现高血压组的生长素释放肽血浆浓度和生长素释放肽与肥胖抑制素的比率均显着低于对照组(236.3 +/- 12.3 pg / ml与381.4 +/- 25.6 pg / ml,P <0.01; 0.89+ /-0.06与1.2 +/- 0.06,P <0.01)。高血压组血浆雌激素含量低于对照组,但两组之间差异无统计学意义(276.2 +/- 15.1 pg / ml vs 325.4 +/- 25.8 pg / ml,P> 0.05)。在多元回归模型中,收缩压,甘油三酸酯和肥胖抑制素是生长激素释放肽的独立预测因子(标准系数= -0.332; P = 0.019;标准系数= -0.302; P = 0.030;标准系数= 0.630; P <0.0005) 。在另一个多元回归模型中,只有生长素释放肽是肥胖抑制素的独立预测因子(标准化系数= 0.861; P <0.0005)。收缩压和甘油三酸酯都是生长素释放肽与肥胖抑制素比率的独立预测因子(标准系数= -0.385; P = 0.033;标准系数= -0.430; P = 0.018)。我们的数据表明,在人的循环血浆中存在生长激素释放肽和肥胖抑制素的干扰,生长激素释放肽/奥贝他汀系统可能在血压调节中起作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号